BioMarin Pharmaceutical Inc.
BMRN
$60.43
$1.903.25%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 348.90M | 520.42M | 657.24M | 523.88M | 426.86M |
| Total Depreciation and Amortization | 72.16M | 82.73M | 83.25M | 91.15M | 96.43M |
| Total Amortization of Deferred Charges | 7.40M | -- | -- | -- | -- |
| Total Other Non-Cash Items | 693.20M | 523.59M | 318.91M | 286.71M | 265.95M |
| Change in Net Operating Assets | -293.66M | -212.76M | -292.62M | -201.47M | -216.40M |
| Cash from Operations | 827.99M | 913.98M | 766.77M | 700.26M | 572.84M |
| Capital Expenditure | -103.04M | -81.85M | -71.86M | -76.09M | -85.42M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -285.19M | -285.19M | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -26.01M | 71.65M | 91.28M | 198.58M | 221.92M |
| Cash from Investing | -414.24M | -295.39M | 19.42M | 122.49M | 136.49M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 0.00 | -494.99M | -494.99M | -494.99M |
| Issuance of Common Stock | 14.46M | 15.58M | 20.37M | 42.08M | 49.28M |
| Repurchase of Common Stock | -55.97M | -58.17M | -61.91M | -66.39M | -77.56M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -889.00K | -94.00K | -3.12M | -3.14M | -3.18M |
| Cash from Financing | -42.39M | -42.69M | -539.65M | -522.43M | -526.45M |
| Foreign Exchange rate Adjustments | -2.52M | -1.24M | -4.88M | 1.49M | 4.83M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 368.84M | 574.66M | 241.67M | 301.81M | 187.72M |